In contrast to BRCA1/BRCA2 variant carriers, a high frequency of ductal carcinoma in situ (DCIS) is observed, with estimates up to 25% [52,53], and it is likely that this fraction will increase with systematic annual breast MRI in carriers. Here, BRCA2 is linked to ductal breast carcinoma in situ.